Biotechnology

KALA BIO

KALA BIO released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.14 (forecast USD -8.5)

KALA BIO released FY2025 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 2.7041 (forecast USD -16)

KALA BIO released FY2025 Annual Earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.3111 (forecast USD -4.45)

KALA BIO released FY2025 9 Months Earnings on November 19 (EST), with actual revenue of USD 0 and EPS of USD -4.1966

KALA BIO released FY2025 Q3 earnings on November 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -53.7029 (forecast USD -50.5)

KALA BIO released FY2025 Semi-Annual earnings on August 8 (EST), actual revenue USD 0, actual EPS USD -156.3153

KALA BIO released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.7126 (forecast USD -1.7033)

KALA BIO's CFO Sells Shares

H.C. Wainwright lowers KALA BIO target price to $12

KALA BIO released FY2025 Q1 earnings on May 14, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -1.4098 (forecast USD -2.03)

KALA BIO released FY2024 Q4 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -87.0681 (forecast USD -114)

KALA BIO released FY2024 annual earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -507.2509 (forecast USD -541.75)

KALA BIO released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -96.7023 (forecast USD -121.5)

KALA BIO released FY2024 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -464.61

KALA BIO released FY2024 Semi-Annual earnings on August 6, 2024 (EST), with actual revenue of USD 0 and actual EPS of USD -365.9855

KALA BIO released FY2024 Q2 earnings on August 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -158.06 (forecast USD -220.25)

KALA BIO released FY2024 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.1969 (forecast USD -2.89)

KALA BIO released FY2023 Q4 earnings on March 29 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -3.1804 USD (forecast -3.62 USD)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

KALA

LABU

IBBQ

ARKG

SBIO

KALA BIO, Inc. reported a net loss of $(1.6M) in Q1 2026, an improvement from $(8.9M) in Q1 2025, with diluted EPS at $(0.14) compared to $(70.49) a year prior. The company is pivoting to an AI platform for biotech and pharma, focusing on asset monetization and operational cost reductions, including ceasing KPI-012 development. They have also executed a licensing agreement for the Researgency Platform.

TradingView

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary

Kala Bio fell 10.58% in after-hours trading; Moderna rose 0.06% in after-hours trading, with a transaction volume of USD 482,000; BeiGene fell 0.54% in after-hours trading, with a transaction volume of USD 444,600; GRAIL fell 0.45% in after-hours trading, with a transaction volume of USD 108,900

Price Alert

Moderna

Beigene

GRAIL

U.S. stock night market volatility: Kala Bio fell 10.58% in after-hours trading, with no significant news but showing volatility. What is causing such market sentiment?

KALA BIO, Inc. (NASDAQ:KALA) is set to undergo a 1-50 reverse stock split on May 11th, following an announcement on May 7th. Share adjustments will occur after market close on May 8th. The stock has seen significant volatility, trading down to $0.08 recently, with a market cap of $77.24 million. Analysts have mixed ratings, with one Buy, four Hold, and one Sell. KALA BIO focuses on developing therapies for ocular diseases, including its FDA-approved product, Eysuvis.

Market Beat

Invesco Biotechnology & Genome ETF

Virtu Finc

KALA BIO Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:KALA)

KALA BIO shares are trading lower after the company announced a 1-for-50 reverse stock split.

benzinga_article

VG Health

iShares Global Healthcare

iShares US Pharma

MLEC

RMBS

VIVK

POET

SMFG

MUFG

In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology and pharmaceutical stocks performing particularly well. The strong rise of Moolec Science SA has attracted market attention, with an increase of 37.58%, indicating enthusiasm from short-term funds. On the other hand, individual stocks such as Rambus and Vivakor have experienced significant declines, dropping 15.08% and 13.10% respectively, reflecting fluctuations in market sentiment and caution among investors. Overall, it seems that short-term enthusiasm is switching between small-cap stocks and thematic stocks, with considerable volatility and complex investor sentiment. The notable increase of 37.58% in Moolec Science SA, the most active stock in the past hour, appears to be driven by market expectations for its new products, leading to a rapid influx of short-term funds and a warming of overall sentiment. In contrast, the decline of Rambus stands out sharply, with a drop of 15.08% reflecting market concerns about its future prospects and a clear outflow of funds. Strong stocks include: 1. KALA BIO: up 11.64%, driven by optimistic expectations for its new drug development. 2. Sumitomo Mitsui Financial: up 4.67%, performing well in the financial sector with stable fund inflows. 3. Mitsubishi UFJ Financial: up 4.07%, benefiting from the market's reassessment of financial stocks, with active short-term fund involvement

Moolec Science SA

Rambus

Vivakor

POET Tech

Sumitomo Mitsui Financial

Mitsubishi UFJ Financial

U.S. stock movement quick report: Moolec Science surged 37.58%, Rambus plummeted 15.08%, attracting market attention

TRVI

ADVB

SCNI

In Monday's after-market session, several health care stocks experienced notable movements. Gainers included Kala Bio (+7.2% to $0.13), Prothena Corp (+6.39% to $11.48), Revolution Medicines (+6.32% to $140.0), BioAtla (+6.2% to $4.79), Adagio Medical Holdings (+6.05% to $1.22), and Trevi Therapeutics (+4.55% to $14.92). Conversely, Erasca saw a significant decline of 25.0% to $14.37, followed by Advanced Biomed (-6.9% to $5.0), EUDA Health Holdings (-5.99% to $12.09), iTonic Holdings (-5.68% to $0.38), Aspire Biopharma Holdings (-5.43% to $0.23), and Scinai Immunotherapeutics (-5.02% to $0.57).

Trevi Therapeutics

Advanced Biomed

Scinai Immunotherapeutics

Adagio Medical

Prothena

BioAtla

Revolution Medicines

iTonic

Euda Health

Erasca

iShares US Healthcare Providers

iShares US Medical Devices

SPDR S&P Health Equip

Health Care Select Sector SPDR

Aspire Biopharma

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Euda Health - CW22

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

12 Health Care Stocks Moving In Monday's After-Market Session

KALA BIO (NASDAQ:KALA) reported quarterly earnings of $0.86 per share. The stock fell 12% to $0.20, with a trading volume of 3.3 million shares. Institutional investors have recently increased their stakes, with 24.61% of shares owned by hedge funds. Analysts have mixed ratings, with one Buy, four Hold, and one Sell, and an average price target of $20.38. KALA BIO focuses on developing therapies for ocular diseases, including its FDA-approved product Eysuvis.

KALA BIO (NASDAQ:KALA) Posts Quarterly Earnings Results

Earnings Watch

KALA BIO | 10-K: FY2025 Revenue: USD 0

KALA BIO reported a significant operating loss of $39.16 million and a net loss of $26.98 million for the year ending December 31, 2025. The company is shifting its focus from MSC-S biologics to an AI platform named Researgency, targeting biotech and pharmaceutical clients. Following the failure of the CHASE Phase 2b trial for KPI-012, KALA BIO is restructuring its operations, including workforce reductions and asset monetization strategies, to align with its new AI initiative.

KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M

KALA BIO(KALA.US)